This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-07-26. Anything still debated is marked as such rather than presented as settled.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
== Corporate governance == As of July 2026, Biocon remains chaired by Mazumdar-Shaw. Effective 1 April 2026, Shreehas Tambe was appointed Chief Executive Officer and Managing Director of Biocon Limited—the first CEO of the integrated company following the full integration of Biocon Biologics Limited as a wholly owned subsidiary; Kedar Upadhye was appointed Chief Financial Officer. Tambe succeeded Siddharth Mittal, who resigned effective 31 March 2026 and moved to another leadership role within the Biocon Group. Mittal had led the company since December 2019, when he replaced CEO and Managing Director Arun Chandavarkar. In 2021, Christiane Hamacher resigned as CEO of Biocon Biologics India Limited, following differences with Mazumdar-Shaw. Hamacher had been appointed to that role in March 2019.
The use of adsorbent chemicals, such as zeolites, and other hemostatic agents are also used for sealing severe injuries quickly (such as in traumatic bleeding secondary to gunshot wounds). Thrombin and fibrin glue are used surgically to treat bleeding and to thrombose aneurysms. Hemostatic Powder Spray TC-325 is used to treated gastrointestinal bleeding. Desmopressin is used to improve platelet function by activating arginine vasopressin receptor 1A. Coagulation factor concentrates are used to treat hemophilia, to reverse the effects of anticoagulants, and to treat bleeding in people with impaired coagulation factor synthesis or increased consumption. Prothrombin complex concentrate, cryoprecipitate and fresh frozen plasma are commonly used coagulation factor products. Recombinant activated human factor VII is sometimes used in the treatment of major bleeding. Tranexamic acid and aminocaproic acid inhibit fibrinolysis and lead to a de facto reduced bleeding rate. Before its withdrawal, aprotinin was used in some forms of major surgery to decrease bleeding risk and the need for blood products.
== Principles and ethical foundations == Across its applications, harm reduction prioritizes reducing adverse consequences without requiring elimination of the underlying behavior. In drug policy, this orientation is commonly described as pragmatic: it begins from the continued existence of drug use and regards reductions in harm as worthwhile outcomes even when abstinence is not achieved. Ethical defenses have also drawn on consequentialist and rights-based reasoning. Consequentialist arguments emphasize reductions in illness, death, and social costs, while rights-based arguments appeal to autonomy and opposition to paternalism. The harm can be distinguished in physical harms, dependence and social harms including health care costs and community outcomes. Social justice approaches broaden the analysis of harm beyond individual behavior to include poverty, homelessness, criminalization, violence, stigma, and barriers to health care. From this perspective, harm reduction may respond to structural inequities as well as immediate individual risk. Relational and participatory approaches emphasize that people who use drugs possess knowledge relevant to effective services and should participate in their design and governance. User-led organizations and peer practices have been important within this tradition. Ethical analysis of harm-reduction research has also used communitarian approaches, emphasizing social relationships and responsibilities alongside individual rights.
Sources: en.wikipedia.org
Tea was first introduced to Western priests and merchants in China during the 16th century, at which time it was termed chá. The earliest European reference to tea, written as chiai, came from Delle navigationi e viaggi written by Venetian Giambattista Ramusio in 1545. The first recorded shipment of tea by a European nation was in 1607 when the Dutch East India Company moved a cargo of tea from Macao to Java, then two years later, the Dutch bought the first assignment of tea which was from Hirado in Japan to be shipped to Europe. Tea became a fashionable drink in The Hague in the Netherlands, and the Dutch introduced the drink to Germany, France, and across the Atlantic to New Amsterdam (New York). In 1567, Russian people came in contact with tea when Cossack leaders (atamans) Petrov and Yalyshev visited China. The Mongolian Khan donated to Tsar Michael I four poods (65–70 kg) of tea in 1638. According to Jeremiah Curtin, it was possibly in 1636 that Vassili Starkov was sent as envoy to the Altyn Khan. He was given 250 pounds of tea as a gift to the tsar. Starkov at first refused, seeing no use for a load of dead leaves, but the Khan insisted. Thus was tea introduced to Russia. In 1679, Russia concluded a treaty on regular tea supplies from China via camel caravan in exchange for furs. It is today considered the de facto national beverage.
Following this Macdonald and Jim Aiken rigged a temperature probe to Alvin to measure the water temperature at the black smoker vents. This observed the highest temperatures then recorded at deep sea hydrothermal vents (380±30 °C). Analysis of black smoker material and the chimneys that fed them revealed that iron sulfide precipitates are the common minerals in the "smoke" and walls of the chimneys.
== External links == HLA-B27 Syndromes at eMedicine by A. Luisa Di Lorenzo, MBBCh Bowness, P. (1 August 2002). "HLA B27 in health and disease: a double-edged sword?". Rheumatology. 41 (8): 857–868. doi:10.1093/rheumatology/41.8.857. PMID 12154202. Online Mendelian Inheritance in Man (OMIM): 142830 HLA-B27 at the U.S. National Library of Medicine Medical Subject Headings (MeSH) BASDAI and Ankylosing Spondylitis National Library of Medicine - Papers on HLA B-27
Mahathir received numerous awards and recognitions, including the Royal Family Order of Brunei (1997), Order of Mubarak the Great (1997), Honorary Ph.D. in Humanities from the National University of Mongolia (1997), Honorary Ph.D. in literature from Al-Azhar University (1998), U Thant Peace Award from the United Nations Organization (1999), Order of Merit of the Republic of Poland (2002), Russian Order of Friendship (2003), Honorary Ph.D. from Tsinghua University (2004), Honorary Ph.D. from the University of Santo Tomas (2012), Honorary Ph.D. in Laws from the National University of Singapore (2018), Japanese Order of the Paulownia Flowers (2018), Honorary Ph.D. from Qatar University (2019), Honorary Ph.D. from the International University of Japan (2019), Nishan-e-Pakistan (2019), and the Order of the Republic of Turkey (2019).
Sources: en.wikipedia.org
Skeletal muscle serves as a storage site for amino acids, creatine, myoglobin, and adenosine triphosphate, which can be used for energy production when demands are high or supplies are low. If metabolic demands remain greater than protein synthesis, muscle mass is lost. Many diseases and conditions can lead to this imbalance, either through the disease itself or disease associated appetite-changes, such as loss of taste due to COVID-19. Causes of muscle atrophy, include immobility, aging, malnutrition, certain systemic diseases (cancer, congestive heart failure; chronic obstructive pulmonary disease; AIDS, liver disease, etc.), deinnervation, intrinsic muscle disease or medications (such as glucocorticoids).
Gender inequalities in France affect several areas, including family life, education, employment, health, and political participation. The United Nations Development Programme (UNDP) monitors gender disparities through the Gender Inequality Index (GII), which evaluates reproductive health, empowerment, and labor market participation.
=== Britain, Australia, and New Zealand === Lamb A young sheep which is less than one year old. From 1 July 2019, the Australian definition is "an ovine animal that: (a) is under 12 months of age, or (b) does not have any permanent incisor teeth in wear". This new definition meant that Australian farmers could extend the term "lamb" by another month. This followed a similar definition change in New Zealand in 2018. In Britain the definition is still "0 permanent incisor teeth". A permanent incisor tooth is said to be "in wear" if it protrudes further than the nearest milk teeth. Hogget A sheep of either sex having no more than two permanent incisors in wear. The term is also used to refer to meat from the aforementioned animal. In the UK, it means animals that are 11 to 24 months old, while Australian butchers use the term for animals that are 13 to 24 months old. Still common in farming usage and among speciality butchers, it is now a rare term in British, Australian and New Zealand supermarkets, where meat of all sheep less than two years old tends to be called "lamb". Mutton The meat of a female (ewe) or castrated male (wether) sheep having more than two permanent incisors in wear.
In 1949, its genetic transmission was determined by E. A. Beet and J. V. Neel. In 1954, it was established that carriers of the abnormal gene are protected to some degree against malaria, which accounts for its persistence in populations threatened by malaria.
=== D-amino acids === Some amino acids contain the opposite absolute chirality, chemicals that are not available from normal ribosomal translation and transcription machinery. Most bacterial cells walls are formed by peptidoglycan, a polymer composed of amino sugars crosslinked with short oligopeptides bridged between each other. The oligopeptide is non-ribosomally synthesised and contains several peculiarities including D-amino acids, generally D-alanine and D-glutamate. A further peculiarity is that the former is racemised by a PLP-binding enzymes (encoded by alr or the homologue dadX), whereas the latter is racemised by a cofactor independent enzyme (murI). Some variants are present, in Thermotoga spp. D-Lysine is present and in certain vancomycin-resistant bacteria D-serine is present (vanT gene).
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.